These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 20458280)
21. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression. Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041 [TBL] [Abstract][Full Text] [Related]
22. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Muñoz M; Martinez-Armesto J; Coveñas R Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287 [TBL] [Abstract][Full Text] [Related]
23. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy? Robinson P; Coveñas R; Muñoz M Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620 [TBL] [Abstract][Full Text] [Related]
24. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist. Munoz M; Recio S; Rosso M; Redondo M; Covenas R J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224 [TBL] [Abstract][Full Text] [Related]
25. Cancer progression and substance P. Coveñas R; Muñoz M Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838 [TBL] [Abstract][Full Text] [Related]
26. The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors. Kolorz J; Demir S; Gottschlich A; Beirith I; Ilmer M; Lüthy D; Walz C; Dorostkar MM; Magg T; Hauck F; von Schweinitz D; Kobold S; Kappler R; Berger M Curr Oncol; 2021 Dec; 29(1):94-110. PubMed ID: 35049682 [TBL] [Abstract][Full Text] [Related]
27. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Muñoz M; Rosso M; Pérez A; Coveñas R; Rosso R; Zamarriego C; Soult JA; Montero I Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2567-70. PubMed ID: 15980249 [TBL] [Abstract][Full Text] [Related]
28. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer. Mozafari M; Ebrahimi S; Darban RA; Hashemy SI Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230 [TBL] [Abstract][Full Text] [Related]
29. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825 [TBL] [Abstract][Full Text] [Related]
30. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755 [TBL] [Abstract][Full Text] [Related]
31. Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography. Endo T; Saijo T; Haneda E; Maeda J; Tokunaga M; Zhang MR; Kannami A; Asai H; Suzuki M; Suhara T; Higuchi M Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609595 [TBL] [Abstract][Full Text] [Related]
32. The NK-1 receptor: a new target in cancer therapy. Muñoz M; Rosso M; Coveñas R Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668 [TBL] [Abstract][Full Text] [Related]
33. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari RM Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005 [TBL] [Abstract][Full Text] [Related]
34. The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer. Martín-García D; Téllez T; Redondo M; García-Aranda M Curr Med Chem; 2024; 31(39):6487-6509. PubMed ID: 37861026 [TBL] [Abstract][Full Text] [Related]
35. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant. Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803 [TBL] [Abstract][Full Text] [Related]
36. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663 [TBL] [Abstract][Full Text] [Related]
37. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Navari RM Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233 [TBL] [Abstract][Full Text] [Related]
38. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059 [TBL] [Abstract][Full Text] [Related]
39. Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. Schwartz L; Spitsin SV; Meshki J; Tuluc F; Douglas SD; Wolfe JH J Neurovirol; 2013 Jun; 19(3):219-27. PubMed ID: 23765222 [TBL] [Abstract][Full Text] [Related]
40. The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Muñoz M; Rosso M; González-Ortega A; Coveñas R Cancers (Basel); 2010 Apr; 2(2):611-23. PubMed ID: 24281084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]